期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

细胞色素P450介导的第二代抗抑郁药的药物相互作用 被引量：11

Interactions of the Second-Generation Antidepressants Mediated by Cytochrome P450
下载PDF
导出
摘要 第二代抗抑郁药主要在肝脏经细胞色素P450(CYP450)酶代谢,并且不同程度地对CYP450酶产生抑制,因此该类药物与其他经肝脏CYP450酶代谢的药物合用时会相互作用,并进而影响治疗药物的血药浓度。本文对国内外近年来第二代抗抑郁药与其他精神科中常见的药物合用时产生的相互作用予以综述。 The second-generation antidepressants are metabolized in liver by the cytoehrome 17450 （CYP450）enzyme system. These drugs can inhibit the CYP isozymes to different extent so as to affect the blood concentration of other drugs. This article reviewed the clinically relevant pharmacokinetic drug interactions between the second-generation antidepressants and other common drugs for mental diseases in clinical experiences.
作者 赵莹莹 林凌云
机构地区 汕头大学精神卫生中心
出处 《医学综述》 2010年第6期940-943,共4页 Medical Recapitulate
关键词 抗抑郁药 药物相互作用 细胞色素P450 药物代谢 Second-generation antidepressants Drug interactions Cytochrome P450 Metabolism
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献27

  • 1Preskom SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome p450 2d6:an update(Part I) [J]. Psychiatr Pract ,2003,9(2) :150-158.
  • 2Albers LJ, Reist C, Vu RL, et al. Effect of venlafaxine on imipramine metabolism [ J ]. Psychiatry Res, 2000,96 ( 3 ) : 235 -243.
  • 3Skinner MH,Kuan HY,Pan A,et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers [ J]. Clin Pharmacol Ther,2003,73 ( 3 ) : 170-177.
  • 4Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated[J]. Br J Pharmacal,2007,151 (6) :737-748.
  • 5张石宁,姚辉,李继民,林红,陆水平,尚晓芳,王筱兰,孙静,谭俊华,韩钢.利培酮与氟西汀合并治疗精神分裂症的相互作用[J].中国临床药理学杂志,2009,25(1):11-13. 被引量：7
  • 6于靖,李文标,陈小平,欧阳冬生,翟屹民,王传跃.细胞色素P4501A2活性与奥氮平代谢的相关性研究[J].中国临床药理学杂志,2009,25(3):239-241. 被引量：5
  • 7Ozdemir V, Naranjo CA, Herrmann N, et al. Paroxetine potentiates the central nervous system side effects of perphenazine : Contribution of cytochrome P4502D6 inhibition in vivo[ J ]. Clin Pharmacol Ther, 1997,62 ( 3 ) :334-347.
  • 8Saito M,Yasui FN, Nakagami T, et al. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients[ J]. Clin Psychopharmacol,2005,25 (6) :527-532.
  • 9Spina E,Avenoso A,Salemi M,et al. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline[J]. Pharmacopsychiatry,2000,33(6):213-217.
  • 10Wetzel H, Anghelescu I, Szegedi A, et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: Differential effects of fluvoxamine and paroxetine in a prospective study [J]. J Clin Psychonharmacol . 1998.18 ( 1):2-9.

二级参考文献17

  • 1刘燕,李华芳,王慧芳,王克勋,高哲石,顾牛范.氯氮平、利培酮对精神分裂症病人血糖-胰岛素稳态的影响及相关因素分析[J].上海精神医学,2003,15(5):257-259. 被引量：33
  • 2毛佩贤,王智民,汤宜朗,蒋锋,蔡焯基.精神分裂症住院患者使用抗精神病药现状[J].临床精神医学杂志,2005,15(1):1-2. 被引量：29
  • 3刘素芳,魏平,王世贵,王东平,王云,马慧娟,贾福军.不同剂量氯氮平与精神分裂症患者血脂、血糖代谢的对照研究[J].中华精神科杂志,2005,38(2):82-85. 被引量：31
  • 4Spina E, Avenoso A, Scordo MG, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction [J]. J Clin Psychopharmacol, 2002; 22:419 -423.
  • 5Spina E, Avenoso A, Facciola G, et al. Plasma concentrations of risperldone and 9 - hydroxyrisperldone during combined treatment with paroxetine[ J]. Ther Drug Monit, 2001 ; 23:223 - 227 .
  • 6Hiemke C, Peled A, Jabarin M, et al. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects[J]. J Clin Psychopharmacol,2002 ; 22:502 -506 .
  • 7Lu ML,Lane HY, Chen KP, et al. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients[J]. J Clin Psychopharmacol, 2000 ; 61:594 - 599 .
  • 8Wetzel H, Anghelescu I, Szegedi A, et al. Pharmacokinrtic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study [J]. J Clin Psychopharmacol, 1998 ; 18 : 2 - 9.
  • 9Bondolfi G, Eap CB, Bertschy G, et al. The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychiatric patients[J]. Pharmacopsychiatry, 2002; 35:50-56.
  • 10Aravagiri M, Yuwiler A, Marder SR . Distribution after repeated oral administration of different dose levels of risperidone and 9 - hydroxy - risperidone in the brain and other tissues of rat[ J]. Psychopharmacology, 1998 ; 139:356 - 363.

共引文献13

同被引文献113

引证文献11

二级引证文献34

医学综述
2010年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部